A drug called AV650 (tolperisone HCl) will be given to patients who have spasticity following a spinal cord injury. This study has three purposes: 1. To determine whether AV650 is safe for patients with spinal cord injury; 2. To assess what the body does with AV650 once it is ingested; and, 3. To gather some early evidence as to whether AV650 is effective in treating spasticity in patients with spinal cord injury.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
120
One tablet orally three times a day for 28 days
One tablet orally three times a day for 28 days
Southern California Clinical Research, Inc.
Pasadena, California, United States
University of Miami Miller School of Medicine
Miami, Florida, United States
Shepherd Center, Inc.
Atlanta, Georgia, United States
To assess the safety, tolerability and PK profile of AV650 in subjects with spasticity due to spinal cord injury.
Time frame: 1 month
To determine preliminary efficacy in subjects with spasticity due to SCI
Time frame: 1 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Internal Center for Spinal Cord Injury Kennedy Kreiger Institute
Baltimore, Maryland, United States
Kernan Orthopaedics & Rehab. Hospital
Baltimore, Maryland, United States
Kessler Institute for Rehab.
West Orange, New Jersey, United States
Carolinas Rehabilitation
Charlotte, North Carolina, United States
Jefferson Medical College of Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Hunter Holmes McGuire Veterans Affairs Medical Center
Richmond, Virginia, United States
Rehabilitation Hospital Health Sciences Centre
Winnipeg, Quebec, Canada